Are you ready to leverage the latest evidence on immune checkpoint inhibitors to maximize outcomes for patients with triple-negative breast cancer (TNBC)? Test your knowledge regarding recent and emerging data for neoadjuvant and adjuvant immunotherapy-based regimens in early-stage TNBC. Receive immediate feedback and customized education tailored to your current skill level following your responses to a series of questions. A downloadable personalized education pathway highlighting key efficacy and safety data, guideline-aligned treatment, and clinical consideration for the use and timing of immunotherapy in early-stage TNBC will be made available upon activity completion.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/ai-driven-personalized-learning-pathways-advance-evidence-based-tnbc
- Start Date: 2024-10-25 05:00:00
- End Date: 2024-10-25 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - Commercial Support: Source: Merck (Any division) - Amount: 115000.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest